
Innate Pharma Investor Relations Material
Latest events

Q1 2025
Innate Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Innate Pharma S.A.
Access all reports
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications. It generates its products from the expression platforms based on its phage display and dAb technologies. The company's lead product is NexoBrid, which is a treatment for severe burns that can be used outside of the European Union; and Phase 3 NExoBrid clinical trial is completed in Europe. Innate Pharma S.A. was founded in 2000 as Innate ImmunoPharmaceuticals S.A.; and it changed its name to Innate Pharma S.A. in 2011. Innate Pharma S.A. has operations in Saint Prex, Switzerland; and Sophia Antipolis, France. Innate Pharma S.A is based in Marseille, France.
Key slides for Innate Pharma S.A.


Q1 2025
Innate Pharma S.A.


Q2 2024
Innate Pharma S.A.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
IPH
Country
🇫🇷 France